Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 5, 2011, Pages 1179-1187

  Basso, Michele ^a   Modoni, Anna ^a   Spada, Daniele ^a   Cassano, Alessandra ^a   Schinzari, Giovanni ^a   Lo Monaco, Mauro ^a   Quaranta, Davide ^a   Tonali, Pietro Attilio ^a   Barone, Carlo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

KCa channels; Neurotoxicity; Oxaliplatin; Peripheral nerve excitability; SK3 gene polymorphism

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; POTASSIUM CHANNEL; SMALL CONDUCTANCE CALCIUM DEPENDENT POTASSIUM CHANNEL; TRINUCLEOTIDE; UNCLASSIFIED DRUG;

ACUTE NERVE HYPEREXCITABILITY; ADULT; ADVANCED CANCER; AFTERDISCHARGE; AGE; AGED; ALLELE; ARTICLE; BILE DUCT CANCER; BRONCHOSPASM; CANCER ADJUVANT THERAPY; CANCER GROWTH; CLINICAL ARTICLE; COLD INDUCED PARESTHESIA; COLORECTAL CANCER; CONSCIOUSNESS DISORDER; DIABETES MELLITUS; DISEASE SEVERITY; DNA EXTRACTION; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPNEA; ELECTROGASTROGRAPHY; ERYTHEMA; FASCICULATION; FEMALE; FOOT PARESTHESIA; GASTROCNEMIUS MUSCLE; GENE; GENE SEQUENCE; GENETIC ANALYSIS; GENOTYPE; HAND PARESTHESIA; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPOTENSION; INCIDENCE; JAW TIGHTNESS; MALE; MOTOR NERVE; MOTOR NERVE CONDUCTION; MOTOR UNIT POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCLE ACTION POTENTIAL; MUSCLE CONTRACTION; MUSCLE CRAMP; MYOKYMIA; NERVE CELL MEMBRANE POTENTIAL; NERVE EXCITABILITY; NERVE STIMULATION; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; NEUROTOXICITY; PANCREAS CANCER; PARESTHESIA; PERIORAL PARESTHESIA; PERIPHERAL NERVE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PTOSIS; SENSORY NERVE; SENSORY NERVE ABNORMALITY; SIDE EFFECT; SK3 GENE; SYMPTOM; TIBIAL NERVE; TRINUCLEOTIDE REPEAT; VISUAL FIELD DEFECT; VOLUNTARY MUSCLE CONTRACTION;

AGED; AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; COLORECTAL NEOPLASMS; ELECTROMYOGRAPHY; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, GENETIC; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; STOMACH NEOPLASMS;

EID: 79955570269     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1466-y     Document Type: Article

References (27)

1. CR Culy D Clemett LR Wiseman 2000 Oxaliplatin: a review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies Drugs 60 895 924 11085200 10.2165/00003495-200060040-00005 1:CAS:528:DC%2BD3cXosVSgs7s%3D
2. A de Gramont A Figer H Seymour M Homerin A Hmissi J Cassidy C Boni H Cortes-Funes A Cervantes G Freyer D Papamichael N Le Bail C Louvet D Hendler F de Braud C Wilson F Morvan A Bonetti 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
3. RM Goldberg DJ Sargent RF Morton CS Fuchs RK Ramanathan SK Williamson BP Findlay HC Pilot SR Alberts 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528:DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
4. E Gamelin L Gamelin L Bossi S Quasthoff 2002 Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures Semin Oncol 29 21 33 12422305 10.1053/sonc.2002.35525 1:CAS:528:DC%2BD38XoslWitbw%3D (Pubitemid 35191038)
5. J Cassidy JL Misset 2002 Oxaliplatin-related side-effects: characteristics and management Semin Oncol 29 11 20 12422304 10.1053/sonc.2002.35524 1:CAS:528:DC%2BD38XoslWitb4%3D
6. D Screnci M McKeage 1999 Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches J Inorg Biochem 77 105 110 10626361 10.1016/S0162-0134(99)00135-X 1:CAS:528:DC%2BD3cXlsFSmsQ%3D%3D (Pubitemid 30089089)
7. RH Wilson T Lehky RT Rebecca MG Quinn MK Floeter JL Grem 2002 Acute oxaliplatin-induced peripheral nerve hyperexcitability J Clin Oncol 20 1767 1774 11919233 10.1200/JCO.2002.07.056 1:CAS:528:DC%2BD38XjtFGqsr8%3D (Pubitemid 34273265)
8. TJ Lehky GD Leonard RH Wilson JL Grem MK Floeter 2004 Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy Muscle Nerve 29 387 392 14981738 10.1002/mus.10559 1:CAS:528:DC%2BD2cXivVygu74%3D (Pubitemid 38269758)
9. IK Hart P Maddison J Newsom-Davis A Vincent KR Mills 2002 Phenotypic variants of autoimmune perypheral nerve hyperexcitability Brain 125 1887 1895 12135978 10.1093/brain/awf178
10. + channels are implicated in neuromyotonia Ann Neurol 41 238 246 9029073 10.1002/ana.410410215 1:CAS:528:DyaK2sXhvVeksLc%3D (Pubitemid 27082105)
11. H Adelsberger S Quasthoff J Grosskreutz A Lepier F Eckel C Lersch 2000 The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons Eur J Pharmacol 406 25 32 11011028 10.1016/S0014-2999(00) 00667-1 1:CAS:528:DC%2BD3cXmslOit7o%3D
12. RG Webster KL Brain RH Wilson JL Grem A Vincent 2005 Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels British J Pharmacol 146 1027 1039 10.1038/sj.bjp.0706407 1:CAS:528:DC%2BD2MXht1Ghu7vN (Pubitemid 41722176)
13. F Grolleau L Gamelin M Boisdron-Celle B Lapied M Phelate E Gamelin 2001 A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J Neurophysiol 85 2293 2297 11353042 1:CAS:528:DC%2BD3MXktFylurY%3D (Pubitemid 32440704)
14. M Basso A Cassano A Modoni D Spada N Trigila M Quirino G Schinzari C Barone 2008 A reversibile coma after oxaliplatin administration suggests a pathogenetic role of electrolyte imbalance Eur J Clin Pharmacol 64 739 741 18350285 10.1007/s00228-008-0474-x
15. T Kimura MP Takahashi H Fujimura S Sakoda 2003 Expression and distribution of a small-conductance calcium-activated potassium channel (SK3) protein in skeletal muscles from myotonic muscular dystrophy patients and congenital myotonic mice Neurosci Lett 347 191 195 12875918 10.1016/S0304- 3940(03)00638-4 1:CAS:528:DC%2BD3sXls1ClsLc%3D (Pubitemid 37271949)
16. O Wittekindt A Jauch E Burgert L Scharer H Holtgreve-Grez G Yvert G Imbert J Zimmer MR Hoehe JP Macher P Chiaroni D van Calker MA Crocq DJ Morris-Rosendahl 1998 The human small conductance calcium-regulated potassium channel gene (hSKCa3) contains two CAG repeats in exon 1, is on chromosome 1q21.3 and shows a possible association with schizophrenia Neurogenetics 1 259 265 10732800 10.1007/s100480050038 1:CAS:528:DyaK1MXns1Cmu78%3D (Pubitemid 128685082)
17. KG Chandy E Fantino O Wittekindt K Kalman LL Tong TH Ho GA Gutman MA Crocq R Ganguli V Nimgaonkar DJ Morris-Rosedahl JJ Gargus 1998 Isolation of a novel potassium channel gene hSKCa3 containing a polymorphic CAG repeat: a candidate gene for schizophrenia and bipolar disorder Mol Psychiatry 3 32 37 9491810 10.1038/sj.mp.4000353 1:CAS:528:DC%2BD3cXls1Gls78%3D (Pubitemid 28045182)
18. + channel, hSK3 Cell Physiol Biochem 18 165 176 17167222 10.1159/000097665 1:CAS:528:DC%2BD28Xht12kur7M (Pubitemid 44946973)
19. SA Miller DD Dykes HF Plensky 1988 A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acid Res 16 1215 3344216 10.1093/nar/16.3.1215 1:CAS:528:DyaL1cXhsVKlsrs%3D
20. CP Austin DJ Holder L Ma LA Mixson CT Caskey 1999 Mapping of hKCa3 to chromosome 1q21 and investigation of linkage of CAG repeat polymorphism to schizophrenia Mol Psychiatry 4 261 266 10395216 10.1038/sj.mp.4000548 1:CAS:528:DC%2BD3cXlvVWktrY%3D (Pubitemid 29292176)
21. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS (2008) Intermittent oxaliplatin (oxali) administration and time-to-treatment failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 26:(abstract 4010)
22. CC McIntyre AG Richardson WM Grill 2002 Modeling the excitability of mammalian nerve fibers: influence of afterpotentials on recovery cycle J Neurophysiol 87 995 1006 11826063 (Pubitemid 34670861)
23. OH Wittekindt V Visan H Tomita F Imtiaz JJ Gargus F Lehmann-Horn S Grissmer DJ Morris-Rosendahl 2004 An apamin- and scyllatoxin-insensitive isoform of the human SK3 channel Mol Pharmacol 65 788 801 14978258 10.1124/mol.65.3.788 1:CAS:528:DC%2BD2cXhs1Kgur0%3D (Pubitemid 38264047)
24. + channels antibodies in acquired neuromyotonia Ann Neurol 56 440 444 15349875 10.1002/ana.20221 1:CAS:528:DC%2BD2cXotFyhs7Y%3D (Pubitemid 39166567)
25. + channels iKCA1 potentiates Ca2+ influx and degranulation in human lung mast cells J Allergy Clin Immunol 114 66 72 15241346 10.1016/j.jaci.2004. 04.005 1:STN:280:DC%2BD2czjvVGjtQ%3D%3D (Pubitemid 39005119)
26. Maindrault-Goebel F, Andrè T, Tournigand C, Louvet C, Perez-Staub N, Zaghib N, de Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patinets. Eur J Cancer 41:2262-2267. [Epub 2005 Sep 9]
27. Siu SW, Chan RT, Au GK (2006) Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 17:259-261. [Epub 2005 Nov 9] (Pubitemid 43160115)